XENE Xenon Pharmaceuticals Inc.: institutional ownership and insider trading
326 funds reported holding $6.45B of Xenon Pharmaceuticals Inc. in their latest 13F filings; in Q2 2026 funds net sold $122M, with 45 new positions and 23 funds selling out; over the last 12 months insiders bought $1.68M and sold $22.0M on the open market; over its last four quarters it reported revenue of $0 and net income of −$409M.
XENE revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$111M, EPS -1.11
- Quarter ended Mar 31, 2026: revenue $0, net income −$102M, EPS -1.17
- Quarter ended Dec 31, 2025: revenue $0, net income −$105M, EPS -1.31
- Quarter ended Sep 30, 2025: revenue $0, net income −$90.9M, EPS -1.15
Famous investors holding XENE
- Stanley Druckenmiller (Duquesne Family Office): $14.4M, 0.3% of the portfolio
- Two Sigma (Two Sigma Investments): $99.2M, 0.1% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $11.3M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $87.4M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $22.7M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $13.5M, 0.0% of the portfolio
Largest institutional holders of XENE
- FMR LLC — $582M
- BlackRock, Inc. (BLK) — $454M
- Avoro Capital Advisors LLC — $349M
- Polar Capital Holdings Plc — $276M
- DRIEHAUS CAPITAL MANAGEMENT LLC — $267M
- Jupiter Topco LLC — $253M
- JANUS HENDERSON GROUP PLC (JHG) — $243M
- PRICE T ROWE ASSOCIATES INC /MD/ — $196M
- JPMORGAN CHASE & CO (JPM, AMJB, VYLD, JPM-PC, JPM-PD, JPM-PJ, JPM-PK, JPM-PL, JPM-PM) — $157M
- Capital International Investors — $143M
Recent XENE insider trades
- Sep 30, 2026: Mortimer Ian bought 30,000 shares ($1.12M)
- Sep 30, 2026: Kelly Thomas Patrick bought 15,000 shares ($560K)
- Aug 28, 2026: Kenney Christopher John sold 7,068 shares ($426K)
- Aug 11, 2026: Gannon Steven sold 10,000 shares ($641K)
5%+ owners
- FMR LLC: 10.3% (Schedule 13G/A, filed Aug 7, 2026)
- Avoro Capital Advisors LLC: 6.3% (Schedule 13G/A, filed May 15, 2026)
Who owns the most XENE stock?
The largest institutional holders of Xenon Pharmaceuticals Inc. in the latest 13F filings are FMR LLC ($582M), BlackRock, Inc. (BLK) ($454M), Avoro Capital Advisors LLC ($349M).
Are insiders buying or selling XENE?
Over the last 12 months insiders bought $1.68M and sold $22.0M of Xenon Pharmaceuticals Inc. stock on the open market (SEC Form 4).
Which famous investors own XENE?
Stanley Druckenmiller, Two Sigma, Renaissance Technologies, Ken Griffin, Izzy Englander.
What was XENE's revenue last quarter?
Xenon Pharmaceuticals Inc. reported revenue of $0 for the quarter ended June 30, 2026, with net income of −$111M.
Which ETFs hold XENE?
107 ETFs and mutual funds hold it among their top 100 positions, including IWM, FSSNX, FHCLX, HLGEX.